MDT and OBIO Related Headlines
Go Back- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed targets BACKBEAT trial completion by Q3 2026
- Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
- Orchestra BioMed receives $20 million from Medtronic under financing pact
- Orchestra BioMed receives $15 million from Ligand under financing agreement
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
- Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
- Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
- Orchestra BioMed presents data showing sustained blood pressure drops
- Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
- Orchestra BioMed publishes clinical data on blood pressure therapy
- Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
- Orchestra BioMed raises $111 million through equity offerings and partnerships
- Ligand and Medtronic invest $70 million in Orchestra BioMed
- Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
MDT and OBIO Related Press Releases
Go Back- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
- Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
- Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
- Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
- Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
- Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
- Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
